Plant Extract Composition Modulating Intestinal Microbiota for IBD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis are ineffective in modifying the intestinal microbiota, leading to persistent inflammation and side effects, with no curative treatment available, and are associated with dysbiosis characterized by an imbalance in Bacteroidetes/Firmicutes ratio and reduced Akkermansia municiphila and Roseburia spp. abundance.
Innovation Solution
A composition comprising extracts from plants such as Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus, and Piper, which modulates the intestinal microbiota by increasing Akkermansia municiphila and Roseburia spp. abundance and reducing the Bacteroidetes/Firmicutes ratio, thereby serving as a drug or nutritional product for the prevention and treatment of IBD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for IBD, then inflammation control is achieved during remission phases, but the intestinal microbiota remains unmodified leading to persistent dysbiosis and disease recurrence
Solution Approach 1:
The patent uses plant extracts as intermediary substances that mediate between the host and microbiota. Specifically, extracts from Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus, and Piper are employed to modulate the intestinal microbiota composition, increasing beneficial bacteria like Akkermansia municiphila and Roseburia spp., thereby addressing dysbiosis without directly targeting inflammation
Solution Approach 2:
The treatment enables the patient's own microbiota to restore balance through the action of plant extracts. The microbiota itself becomes the therapeutic agent by regaining proper composition and function, reducing dependency on external anti-inflammatory medications and their associated side effects
2Reliability
If current IBD treatments are administered, then symptoms are managed during remission, but side effects occur including bone density loss, weight gain, and potential disease exacerbation
Solution Approach 1:
The patent employs plant-based extracts that act as temporary, natural interventions rather than long-term pharmaceutical dependencies. These extracts provide symptom management while avoiding the cumulative toxic effects of conventional medications, allowing patients to discontinue harmful treatments once microbiota balance is restored
Solution Approach 2:
The treatment changes the fundamental parameter of microbiota composition rather than merely suppressing symptoms. By modifying the microbial ecosystem through plant extracts, the underlying cause of inflammation is addressed, leading to sustained symptom relief without the side effects associated with immunosuppressive drugs
3Use of energy by moving object
If high-fat diet is consumed, then energy intake is increased, but intestinal inflammation is promoted at the cellular level and intestinal barrier function is disrupted
Solution Approach 1:
The patent converts the harmful effect of dietary fats on intestinal inflammation into a beneficial outcome by using plant extracts that selectively modulate microbiota. The extracts promote the growth of beneficial bacteria that can metabolize fats more effectively and reduce inflammation, thereby allowing energy intake without the harmful inflammatory effects
Data Source
AI summary
The invention relates to a composition comprising at least one specific mixture of molecules for use as a drug or nutritional product in the prevention and/or treatment of chronic inflammatory bowel diseases in humans or animals.